Is the secretion of atrial natriuretic peptide in man under neural control?

McDowell, Garry; Cave, M.; Bainbridge, Anthony; Danton, Mark; Shaw, Christopher; Buchanan, K.D.; Wallwork, J.; Large, Stephen; Nicholls, D. P.

doi:10.1053/euhj.1999.1876

Cited by 11 publications

(5 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intermittent raised levels of ANP were observed in healthy men, with peaks occurring every 9 min, and long-term oscillations with duration of 34 min. We had also previously observed intermittent raised levels of ANP in healthy men, and in patients with CCF, with peaks occurring every 6±10 min [12]. The present study showed a similar frequency of peaks in the peptides studied.…”

Section: Discussionsupporting

confidence: 90%

“…Plasma levels of c-terminal atrial natriuretic peptide (cANP) have been observed to be uneven and our previous work [11] has shown that increased levels occur transiently, with the periodicity of peaks and troughs approximately every 10±12 min. This pro®le is also maintained, and indeed exaggerated, in patients with CCF [11] and after cardiac transplantation [12]. Recently this observation has been extended to include c-terminal brain natriuretic peptide (cBNP) [13].…”

Section: Introductionmentioning

confidence: 97%

See 1 more Smart Citation

Neuropeptide variability in man

Onuoha¹,

Nugent²,

Hunter³

et al. 2000

Eur J Clin Investigation

View full text Add to dashboard Cite

The data demonstrate marked variability in circulating levels of the neuropeptides studied. In addition, peaks and troughs were observed every 10-15 min from all three vascular beds. If these peptides are secreted in a pulsatile pattern, then interpretations of single measurements should be guarded. Furthermore, this study raises interesting questions about the physiology of hormone secretion in man.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Introductionmentioning

confidence: 97%

Neuropeptide variability in man

Onuoha¹,

Nugent²,

Hunter³

et al. 2000

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

“…In our previous study on C‐ANP [6] we observed no changes in heart rate or right atrial pressure during the 90‐min sampling time to coincide with the ‘peaks’, even though an increase in right atrial wall stress has been identified as the main stimulus of ANP secretion [15]. Neural control has been excluded by studies in the denervated heart [16], and so the exact mechanism behind the ‘peaks’ remains obscure.…”

Section: Discussionmentioning

confidence: 98%

Variability of Nt‐proANP and C‐ANP

McDowell

Patterson

Maguire

et al. 2002

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

“…The mechanism of synthesis and secretion of ANP and BNP is not fully understood, but the larger amplitude of oscillations in patients with CHF might be due to a more intense synthesis of ANP and BNP as found in heart failure [18,28], to different modulation of the secretion of pressure hormones being augmented in heart failure [29,30] and\or to differences in cardiac innervation [31]. It is believed that ANP is stored in granules mainly in the atrium and that the secretion\production is largely regulated by a change in atrial transmural pressure, whereas BNP is constitutively released in the ventricle [32], although ANP and BNP have been found to coexist in the same granules in the atrium and to a lesser extent in the ventricle [33].…”

Section: Discussionmentioning

confidence: 96%

Abnormal rhythmic oscillations of atrial natriuretic peptide and brain natriuretic peptide in heart failure

Bentzen

Pedersen

et al. 2003

Clinical Science

View full text Add to dashboard Cite

The purpose of this study was to clarify whether the secretions of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are pulsatile in patients with chronic heart failure (CHF), and whether the rhythmic oscillations for ANP and BNP are abnormal in patients with CHF. Several reports have shown that ANP and especially BNP are valuable indicators of the prognosis in CHF. Previously, a pulsatile secretion has been described for ANP and BNP in healthy humans and for ANP in CHF patients. More information about the secretion pattern of BNP in heart failure is necessary to increase the clinical usefulness of BNP in patients with CHF. Patients with left ventricular systolic dysfunction and CHF ( n =12) and controls ( n =12) were investigated. Plasma ANP and BNP levels were determined every 2 min during a 2-h period by radioimmunoassay and analysed for pulsatile behaviour by Fourier transformation. All patients and controls had significant rhythmic oscillations in plasma ANP levels, and 11 patients with CHF and 10 controls had significant rhythmic oscillations in plasma BNP levels. The amplitude of the main frequency was considerably higher in patients with CHF than in controls (ANP: CHF, 4.76 pmol/l; controls, 0.75 pmol/l; P <0.01. BNP: CHF, 3.24 pmol/l; controls, 0.23 pmol/l; P <0.001; all values are medians), but the main frequency did not differ significantly between the group with CHF and the control group for either ANP or BNP. Patients with CHF demonstrate pulsatile secretion of ANP and BNP with a much higher absolute amplitude, but with the same main frequency as healthy subjects.

show abstract

Is the secretion of atrial natriuretic peptide in man under neural control?

Cited by 11 publications

References 36 publications

Neuropeptide variability in man

Neuropeptide variability in man

Variability of Nt‐proANP and C‐ANP

Abnormal rhythmic oscillations of atrial natriuretic peptide and brain natriuretic peptide in heart failure

Contact Info

Product

Resources

About